(Reuters) - Merck & Co's
The second-biggest U.S. drugmaker on Tuesday said it earned $906 million, or 30 cents per share, in the second quarter. That compared with $1.79 billion, or 58 cents per share, in the year-earlier period.
Global company revenue fell 11 percent to $11.01 billion, hurt by generic competition for its Singulair asthma drug, which lost U.S. patent protection a year ago. Wall Street had expected company revenue of $11.22 billion.
(Reporting by Ransdell Pierson; Editing by Gerald E. McCormick)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp